Growth hormone peptides compared
CJC-1295 with DAC vs no DAC
Two forms of one growth hormone-releasing hormone analog, with each figure tied to its own study or regulator page.
A 2026 review states that the DAC modification enables binding to circulating albumin, markedly prolonging exposure, and that CJC-1295 without DAC remains essentially uncharacterised in the peer-reviewed human literature.1 Two trials in healthy adults estimated the half-life of CJC-1295 with DAC at 5.8 to 8.1 days, and the review lists the half-life of the form without DAC as not reported in human studies.2,1
The review states that neither CJC-1295 variant is approved by major regulators such as FDA or EMA, and WADA names CJC-1295 among GHRH analogues prohibited at all times.1,3
| Fact | CJC-1295 with DAC | CJC-1295 (no DAC) |
|---|---|---|
| What it is | One of three maleimido derivatives of human GRF 1-29 in a rat study; its drug affinity complex binds circulating albumin, prolonging exposure7,1 | |
| How it comes | No label was found; given as a single injection in a human study, and subcutaneously in rats4,7 | No label or human dose trial was found; no peer-reviewed human study reports its route, per a review1 |
| Half-life | ||
| Studied doses | No human dose trial was found; no controlled clinical studies have directly evaluated it in humans, per a review1 | |
| Status | FDA names serious adverse events, including increased heart rate and systemic vasodilatory reaction5. WADA names CJC-1295 among GHRH analogues, prohibited at all times3 | Not approved by FDA or EMA, per a review1. The TGA names CJC-1295 among unapproved peptide products10; WADA names it among GHRH analogues, prohibited at all times3 |
Last reviewed . Sources are listed below.
How they differ
After a single injection of CJC-1295 with DAC, mean GH rose 2- to 10-fold for 6 days or more and mean IGF-I 1.5- to 3-fold for 9 to 11 days.2 In healthy men a week after one injection, basal GH levels were markedly increased while the frequency and magnitude of GH pulses were unaltered.4
The review states that claims about CJC-1295 without DAC derive largely from extrapolation from related compounds, mainly GHRH 1-29 (sermorelin), and from non-academic sources.1
Logged in Milligram
- CJC-1295 with DAC: Too few people logged it to show a share.
- CJC-1295 (no DAC): Too few people logged it to show a share.
Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.
What is not known
The 2026 review notes no long term safety data for CJC-1295 with DAC, and FDA states that available clinical data on CJC-1295 are limited.1,5 A registered phase 2 trial of CJC-1295 in HIV patients with visceral obesity is listed as terminated.6 No study was found that gave both forms in the same trial.
References
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Narrative review, 2026. PMC13322892
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal article (two randomized placebo-controlled human trials), 2006. PMID 16352683
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. Anti-doping list, 2026. wada-ama.org
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal article (human study), 2006. PMID 17018654
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator page, 2026. fda.gov
- ConjuChem (sponsor). A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. Registry entry, 2005. NCT00267527
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Journal article (rat study), 2005. PMID 15817669
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Analytical study, 2010. PMID 21204297
- Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. Clinical study, 1994. PMID 7962295
- Therapeutic Goods Administration (Australia). Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Regulator safety advisory, 2026. tga.gov.au